Actively Recruiting
Glaucoma Laser Assessment of Stability and Sustainability
Led by Twin Cities Eye Consultants · Updated on 2025-05-14
48
Participants Needed
1
Research Sites
113 weeks
Total Duration
On this page
Sponsors
T
Twin Cities Eye Consultants
Lead Sponsor
A
Alcon Research
Collaborating Sponsor
AI-Summary
What this Trial Is About
The GLASS Study is designed to help researchers learn whether repeating a non-invasive laser treatment called DSLT (Direct Selective Laser Trabeculoplasty) can better control eye pressure in patients with early-stage glaucoma or ocular hypertension. All participants will receive the laser treatment in both eyes. After three months, one eye will be randomly selected to receive a second treatment, while the other eye will serve as a comparison. The goal is to see whether two treatments work better than one at keeping eye pressure low without using daily eye drops. This study will help doctors decide the best way to use this laser treatment to manage glaucoma and delay the need for medication. Participants will be followed for one year to monitor safety, eye pressure, and the need for any additional treatments.
CONDITIONS
Official Title
Glaucoma Laser Assessment of Stability and Sustainability
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female patients aged 40 years or older
- Diagnosed with ocular hypertension, glaucoma suspect, or mild primary open angle glaucoma in both eyes
- Treatment-naive with intraocular pressure between 21-35 mmHg, with less than or equal to 3 mmHg difference between eyes
- Best corrected visual acuity of 20/50 or better
- Able to understand study requirements and provide written consent
- Willing to follow study procedures and attend all scheduled visits for 12 months
You will not qualify if you...
- Unable to view scleral spur inferiorly with gonioscopy
- Have congenital, developmental, angle closure, secondary, pigmentary, neovascular, closed angle, or uveitic glaucoma
- Currently using oral or ocular hypotensive medications for glaucoma
- Previous ocular surgery except cataract surgery performed at least 2 years prior
- Significant ocular diseases other than cataract and glaucoma, such as neovascular or advanced macular degeneration or proliferative diabetic retinopathy
- Significant ocular inflammation or infection within 6 months before screening
- Previous corneal transplant or significant corneal dystrophy
- Unclear ocular media preventing eye examination
- Uncontrolled systemic disease posing health risk or preventing study completion
- Participating in another investigational drug or device trial within the past 30 days
- Pregnant, nursing, or women of childbearing potential not using acceptable contraception
- Prior ocular procedures allowed only if cataract surgery was at least 2 years ago or YAG capsulotomy at least 60 days before screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Twin Cities Eye Consultants
Coon Rapids, Minnesota, United States, 55433
Actively Recruiting
Research Team
H
Hannah Schoenecker
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here